BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26023085)

  • 1. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
    Vasilevskaya IA; Selvakumaran M; Hierro LC; Goldstein SR; Winkler JD; O'Dwyer PJ
    Clin Cancer Res; 2015 Sep; 21(18):4143-52. PubMed ID: 26023085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
    Selvakumaran M; Amaravadi RK; Vasilevskaya IA; O'Dwyer PJ
    Clin Cancer Res; 2013 Jun; 19(11):2995-3007. PubMed ID: 23461901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin.
    Vasilevskaya IA; Selvakumaran M; O'Dwyer PJ
    Mol Pharmacol; 2008 Jul; 74(1):246-54. PubMed ID: 18436711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy.
    Vasilevskaya IA; Selvakumaran M; Roberts D; O'Dwyer PJ
    Mol Cancer Res; 2016 Aug; 14(8):753-63. PubMed ID: 27216154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
    Selvakumaran M; Yao KS; Feldman MD; O'Dwyer PJ
    Biochem Pharmacol; 2008 Feb; 75(3):627-38. PubMed ID: 18178171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
    Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.
    Lipner MB; Peng XL; Jin C; Xu Y; Gao Y; East MP; Rashid NU; Moffitt RA; Herrera Loeza SG; Morrison AB; Golitz BT; Vaziri C; Graves LM; Johnson GL; Yeh JJ
    JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32213714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
    Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R
    Nutrients; 2018 May; 10(5):. PubMed ID: 29724012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.
    Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
    Cancer Res; 2003 Dec; 63(24):8600-5. PubMed ID: 14695170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
    Yoshii Y; Furukawa T; Aoyama H; Adachi N; Zhang MR; Wakizaka H; Fujibayashi Y; Saga T
    Int J Oncol; 2016 Apr; 48(4):1477-84. PubMed ID: 26820693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.